PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions

Inclusion Criteria: * Subject must be ≥ 18 years old * Subject must receive a first prescription (meaning no known prescription for this drug in the preceding 12 months) for one or more of 42 drugs, for which a Dutch Pharmacogenomic Working Group guideline is available, which is prescribed to them in routine care * Subject is able and willing to take part and be followed-up for at least 12 weeks * Subject is able to donate blood or saliva * Subject has signed informed consent * The study limit of enrolment (200 per arm, per 18-month block) for that drug has not been reached Exclusion Criteria: * Subject has previous (direct-to-consumer, or clinical) genetic testing for a gene important to the drug of inclusion * Subject is pregnant or lactating * Subject has a life expectancy estimated to be less than three months by treating clinical team * Duration of the drug of inclusion total treatment length is planned to be less than seven consecutive days. A drug whose route of administration changes during the first seven days (e.g. intravenous to oral flucloxacillin) but whose total treatment duration is seven days or longer, is still eligible. * For inpatients: hospital admission is expected to be less than 72 hours * Subject is unable to consent to the study * Subject is unwilling to take part * Subject has no fixed address * Subject has no current general practitioner * Subject is, in the opinion of the Investigator, not suitable to participate in the study * Subject has exist…